Table 2.
Baseline features at the time of liver biopsy in 90 patients who underwent liver biopsy between January 2018 and August 2019
| Variable | EUS-guided liver biopsy (n = 30) | PC-guided liver biopsy (n = 60) | P value |
|---|---|---|---|
| Demographics | |||
| Agea | 54 (46–63) | 53 (45–59) | 0.694 |
| Gender, male:female | 11:19 | 22:38 | 1 |
| Indications for LB | |||
| Fibrosis staging, n (%) | 5 (17%) | 43 (72%) | < 0.0001 |
| Elevated liver enzymes, n (%) | 17 (57%) | 10 (17%) | |
| Evaluation of suspected NASH, n (%) | 8 (27%) | 7 (12%) | |
| Liver biopsy properties | |||
| Core length (mm)a | 25 (21–33) | 31 (20–42) | 0.517 |
| Core numbersa | 5 (5–6) | 3 (3–4) | 0.001 |
| Portal tract numbersa | 5 (5–8) | 13 (8–21) | < 0.0001 |
| Fragmented LB sample, yes, n (%) | 12/30 (40%) | 6/60 (10%) | 0.005 |
| Histological diagnosis established, yes, n (%) | 28 (93%) | 60 (100%) | 0.84 |
| Others | |||
| Hospital stay, hoursa | 3 (2.6–3.9) | 4.2 (3–5.9) | 0.004 |
| Pain severitya,b | 0 (0–3) | 3.5 (2–7) | 0.0009 |
| Opiate use, yes, n (%) | 2 (7%) | 29 (48%) | < 0.0001 |
| Readmission, yes, n (%) | 1 (3%) | 0 | 0.303 |
aData are expressed as median (IQR) [Q2: Q1 − Q3]
bPain severity scale ranges from 0 to 10, where 0 is no pain and 10 is intolerable pain